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for moxifloxacin on day 1 and day 24. In treatment group B, placebo 
for ponesimod was administered once daily for 22 days (days 2–23). 
In addition, subjects received a single oral dose of moxifloxacin 400 
mg either on day 1 or day 24. Replicate ECGs were to be extracted 
from the continuous digital 12-lead ECG recording over 12 hours. 
Primary end point was the baseline-adjusted, placebo-corrected 
effect of individual nonlinear corrected QT intervals (Δ Δ QTcI) on 
day 12 (40 mg) and on day 23 (100 mg). The relationship between 
plasma concentrations of ponesimod and metabolites and Δ Δ QTcI 
was assessed by applying a linear mixed effects modeling approach.
Results: Ponesimod caused a small QTc prolongation, with a mean 
peak effect on Δ Δ QTcI of 6.9 ms (upper bound of the 2-sided 90% 
CI, 11.3 ms) on 40 mg and 9.1 ms (upper bound of the 2-sided 90% 
CI, 14.0 ms) on 100 mg. However, upon extrapolation to steady-state 
concentrations reached with 20-mg ponesimod, the upper bound of 
the 2-sided 90% CI would be below 10 ms, and should result in a 
negative study for doses of 20-mg ponesimod or lower. There was no 
relevant increased incidence of QTcI outliers, either as absolute or 
change from baseline, and QTcI > 480 ms or QTcI increase > 60 ms 
from baseline was not observed with ponesimod. Ponesimod did not 
affect the PR or QRS intervals. Assay sensitivity was demonstrated by 
moxifloxacin QTcI response with a mean peak effect on Δ Δ QTcI of 
11.8 ms (lower bound of the 2-sided 90% CI, 9.0 ms).
Conclusion: Ponesimod at doses of 40 mg and 100 mg causes a 
small QTc prolongation. However, based on the concentration-effect 
relationship no clinically relevant effect on QTc interval is expected 
for a dose of 20 mg, the highest selected dose for Phase 3.
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Introduction: Hypoxia is associated with pro-inflammatory condi-
tions and increased risk of cardiovascular diseases. The transcription 
factors hypoxia-inducible factor (HIF)-1 and HIF-2 are known to 
have central roles in oxygen and energy homeostasis. Recent studies 
have shown that HIF-2α is deacetylated and activated by Sirtuin 
(Sirt)1, a nicotinamide adenine dinucleotide (NAD)-dependent 
deacetylase, suggesting that Sirt1 may be involved in resistance to 
hypoxic stress. The aim of our pilot study is to investigate the acute 
role of Sirt in adaptation to hypoxic conditions.
Patients (or Materials) and Methods: Five healthy volunteers inhaled 
a gas mixture of 10% oxygen in nitrogen for 4 to 6 hours. Blood 
samples were taken 2, 4, 6 to 8, and 24 hours after start of inhalation. 
Erythropoietin levels were measured in plasma, and hemoxygenase 1 
(HO-1), nicotinamide phosphoribosyltransferase (Nampt) and Sirt 
levels in peripheral blood mononuclear cells (PBMCs) by Western 
blot and qPCR.
Results: During inhalation of the 10% oxygen gas mixture, paO2 
levels decreased from a mean of 90 mm Hg to 50 mm Hg. Mean 
erythropoietin levels increased from 6.6 to 11.7 mU/mL 6 to 8 hours 
after the start of inhalation. Western blot analysis showed increased 
expressions of HO-1 and Sirt3 after 6 hours. The expression of the 
Sirt substrate Nampt was also increased after 6 and 24 hours. In 
contrast, only a small increase in Sirt1 and Sirt3 mRNA was detected. 
Sirt2 mRNA or protein expression was not altered following hypoxia.
Conclusion: Systemic hypoxia increases Sirt3 protein expression in 
PBMC. This suggests that histone deacetylation of hypoxia-inducible 
factors are affected by changes in Sirt expression in diseases with 
intermittent hypoxia. Drugs targeting Sirt may thus influence adap-
tation to acute hypoxic episodes such as sleep apnea syndrome or 
chronic hypoxic conditions.
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Introduction: In patients undergoing coronary artery bypass graft-
ing (CABG), ischemia-reperfusion (IR) damages myocardial tissue. 
Postoperative plasma troponin is a biomarker of myocardial injury 
and is associated with an adverse outcome. In animals, dipyrida-
mole reduces reperfusion injury by inhibition of the equilibrative 
nucleoside transporter (ENT) and subsequent increase in extracel-
lular adenosine (an activator of intracellular prosurvival pathways). 
In humans, oral dipyridamole significantly inhibits ENT. Cellular 
uptake of adenosine is reduced in subjects with reduced adenosine 
monophosphate deaminase 1 (AMPD1) activity. We hypothesized 
that oral dipyridamole limits myocardial IR-injury in patients under-
going CABG surgery and that this protection is limited to those with 
normal AMPD1 activity.
Patients (or Materials) and Methods: In a double-blind trial, 94 
patients undergoing elective CABG were randomized to pretreat-
ment with either dipyridamole retard (200 mg BID for 3 days) or 
placebo. Patients abstained from caffeine for at least 24 hours. The 
primary end point: plasma troponin-I at 6, 12, and 24 hours after 
CABG (high sensitivity assay, Siemens). Secondary end points bleed-
ing, arrhythmias 24 hours’ postoperatively, the need for prolonged 
inotropic support, and prolonged ICU stay. In all patients, AMPD1 
34C> T variants (CC: normal activity; CT and TT: reduced activity) 
was determined.
Results: Seventy-nine patients were included in the per-protocol 
analysis (46 placebo). Treatment arms did not differ with respect to 
age, gender, cardiovascular medication, cardiovascular risk factors, 
or aortic clamping time. Troponin concentrations increased from 0 
(0–0) to maximally 3.4 (2.4–5.5) in placebo and 3.7 (2.7–6.1) μ g/L 
at 6 hours after reperfusion (median with interquartile range; P > 
0.5 for comparison between treatment arms, mixed model analysis 
after log transformation).This increase in troponin was correlated 
with aortic clamping time (r = 0.3, P < 0.01, Spearman). As for the 
primary end point, secondary end points did not significantly differ 
between the 2 study arms. Analysis restricted to the AMD1 CC vari-
ant provided similar results.
Conclusion: Dipyridamole before CABG does not prevent the rise 
in troponin, regardless of AMPD1 genotype. We confirmed a role 
for IR in this measure of cardiac injury. Therefore, dipyridamole 
does not seem an effective therapy to prevent ischemia-reperfusion 
injury in humans.
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